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Abstract
 
Two outstanding questions concerning antinuclear antibodies (ANAs) in lupus involve their
pathogenic potential and their molecular signatures. To address these questions, a panel of 56
antinuclear and 47 nonnuclear binding monoclonal antibodies was rescued from four seropositive
NZM2410 lupus mice. The monoclonals varied in their reactivity to nucleosomes, ssDNA,
dsDNA, and glomerular substrate. A large fraction of the antibodies demonstrated apparent
polyreactivity (to DNA, histones, and glomerular antigens) due to bound, DNase-1 sensitive
nuclear antigenic bridges. Although nephrophilic immunoglobulin (Ig) M and IgG antibodies
were the most pathogenic, the dsDNA-binding antibodies were modestly so; in contrast, anti-
nucleosome antibodies were clearly not pathogenic. Compared with the nonnuclear antigen-
binding monoclonal antibodies rescued from the same mice, ANAs exhibited increased utilization
of VH5/7183 genes and highly cationic heavy chain (HC) CDR3 regions. Most intriguingly,
the CDR3 regions of the ANAs exhibited alternating arginine/lysine peaks at H96, H98, and
H100, with neutral troughs at H95, H97, and H99. To summarize, glomerular-binding anti-
dsDNA antibodies appear to be the most pathogenic variety of lupus autoantibodies. The
presence of an alternating charge pattern in their HC CDR3 regions appears to be a prominent
hallmark of ANAs.
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Introduction
 
It is well accepted that antinuclear antibodies (ANAs),
anti-DNA Abs in particular, constitute major effectors of
pathology in lupus (1–8). Several papers have already dem-
onstrated that anti-dsDNA Abs can potentially induce
disease when transferred in vivo (4–8). However, it is not
clear if antinucleosome Abs (which bind strongly to nucleo-
somes and histone–DNA complexes, but not to histone-
free DNA) are also pathogenic. Although a subset of lupus
patients harbor predominantly antinucleosome Abs (directed
particularly to H2A–H2B–DNA complexes) in the striking
absence of anti-dsDNA ANAs, this peculiar phenotype is
perhaps the best diagnostic hallmark of drug-induced lupus
(9–10). Importantly, patients with drug-induced lupus, as
well as those with “idiopathic” lupus who bear antinu-
cleosome (but not anti-dsDNA) Abs, are relatively free of
renal disease (11). Burlingame et al. and Amoura et al.
have reported that antinucleosome Abs appear early in
disease, both in humans and in mice with lupus (12–14).
In contrast, anti-dsDNA Abs appear later as the disease
progresses, showing better temporal association with renal
disease. Recent studies in congenic models of lupus also
support the aforementioned notion that antinucleosome
Abs are not associated with disease, whereas anti-dsDNA
Abs are. Thus, although B6.
 
Sle1
 
 mice have high titers of
antinucleosome Abs associated with minimal glomerulo-
nephritis, B6.
 
Sle1
 
.
 
Sle3
 
 and B6.
 
Sle1
 
.
 
FAS
 
lpr
 
 mice exhibit
high titers of anti-dsDNA Abs, accompanied by severe
glomerulonephritis (15–18). On the other hand, isolated
studies have demonstrated that some antinucleosome Abs
may indeed be pathogenic, under certain experimental
contexts (19).
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In addition to anti-DNA and antinucleosome Abs, anti-
bodies specific for laminin, fibronectin, actinin, as well as
polyreactive glomerulotrophic (or nephrophilic) Abs, have
all been shown to be potentially pathogenic (for review see
reference 4). However, we still lack a clear understanding
of how these different Abs compare with each other in
terms of their pathogenic potential. One of the goals of this
work is to rescue these different autospecificities from the
same lupus-afflicted mice and to directly compare their rel-
ative pathogenic capacities.
The second goal of this work is to elucidate the molecu-
lar signatures of ANAs. The few comprehensive papers that
have attempted to directly compare ANAs with non-ANAs
have invariably used Abs drawn from the Kabat Ab database
as controls (for reviews see references 20–26). The use of
the Kabat database yields a large number of control Abs to
compare against. Although the studied ANAs have predom-
inantly been rescued from the BWF1 and MRL/
 
lpr
 
 strains,
the Kabat collection of Abs has been predominantly drawn
from Balb/c and C57BL/6 (B6) mice, which differ from the
lupus-prone strains in their 
 
Ig
 
 allotype. In addition, the Ka-
bat database harbors many clonal replicates, numerous anti-
hapten Abs that are homogenous in sequence, as well as sev-
eral nuclear antigen-reactive Abs. These peculiarities of the
Kabat collection of Abs could potentially lead to a biased
representation of the “normal” or non-ANA repertoire.
Thus, the “molecular signatures” of ANAs that have been
reported previously using the Kabat database as a control
must be interpreted with caution. In this work, we generate
a sizeable panel of ANAs and non-ANAs from the same
strain (and the same mice) to decipher any molecular foot-
prints that may be truly peculiar to ANAs.
We rescued monoclonal autoantibodies from a murine
lupus strain whose antibody repertoire has never been ex-
amined before: the NZM2410 strain, which is an NZB/
NZW recombinant inbred that develops lupus nephritis by
5–6 mo of age (27). A panel of 56 ANAs and 47 non-ANAs
were rescued from seropositive NZM2410 mice. By study-
ing the functional properties and sequence profiles of these
Abs, we aim to advance our understanding of two critical
aspects of ANAs: the pathogenic potential of different anti-
genic fine specificities and their molecular signatures.
 
Materials and Methods
 
Mice.
 
Male and female NZM2410 mice were obtained from
the Jackson Laboratories or from R. Singh (University of Cincin-
nati, Cincinnati, OH), and aged till 5–8 mo of age, when they
were serotested and killed for fusion. 2–4-mo-old male NZW
mice (Jackson Laboratories) were used as recipients for the in vivo
pathogenicity assays. All mice were housed in a specific patho-
gen-free colony, following institutional guidelines.
 
Hybridoma Fusion and mAb Purification.
 
Spleens were re-
moved aseptically from 5–8-mo-old seropositive NZM2410
mice. Single cell suspensions of the splenocytes were added to the
SP2/0 fusion partner, at a 5–7:1 ratio, in 50% PEG. After wash-
ing, the cells were suspended in “fusion medium” (DMEM sup-
plemented with 25% SP2/0 culture supernatant, 20% horse se-
rum, and 1
 
 
 
 HAT) and plated at 5 
 
 
 
 10
 
5
 
 cells/well. All wells
with single colonies were tested for Abs 7–10 d after fusion. Cells
from positive wells were subcloned once more. 1 wk after the
seeding, wells with single colonies were picked for Ab (i.e., total
IgG or IgM) screening by ELISA. Positive wells were expanded,
and multiple freezes were made. IgG Abs from monoclonal hy-
bridoma culture supernatants were purified by precipitation with
50% ammonium sulfate, followed by affinity chromatography us-
ing protein A–Sepharose columns (Pierce Chemical Co.). IgM
antibodies were concentrated from the hybridoma culture super-
natants by precipitation with 50% ammonium sulfate. Ab con-
centration was determined using a Coomassie PLUS protein assay
kit (Pierce Chemical Co.), and an isotype-specific ELISA, as de-
scribed in the next paragraph.
 
ELISA for Ig.
 
The isotypes of the monoclonal antibodies
were determined by ELISA and sequence confirmation. In brief,
for the isotype-specific sandwich ELISA, goat anti–mouse IgM or
goat anti–mouse IgG (Roche) was first coated onto plates (Im-
mulon I; Dynatech) and blocked. Test samples were diluted seri-
ally and added to the plates for 2 h at rt (room temperature).
Bound immunoglobulin was revealed with alkaline phosphatase–
conjugated goat anti–mouse IgM, IgG1, IgG2a, IgG2b, or IgG3
antibodies (Roche or Jackson ImmunoResearch Laboratories) us-
ing p-nitrophenyl phosphate as a substrate. Concentrations were
determined using a standard curve constructed using purified Ab
standards (Sigma-Aldrich).
 
Assay for Specific Antibodies.
 
mAbs were diluted up to 1 
 
 
 
g/
ml and tested by both antinuclear immunofluorescence and
ELISA as described previously (15–17). The antinucleosome
ELISA was performed with a commercially available kit (KMI
Diagnostics) using calf thymus nucleosome as substrate. The glo-
merular-binding ELISA was performed as described previously
(16, 17) using sonicated rat glomeruli as substrate. In brief, renal
cortices of Lewis rats were minced and pressed through a series of
sieves of decreasing pore size (250, 150, and 75 
 
 
 
m). The glom-
eruli were collected on the finest sieve and were 
 
 
 
95% pure. The
glomeruli were washed with cold PBS three times, sonicated for
7 min, and centrifuged at 2,000 
 
g
 
 for 5 min. The supernatant was
used as a substrate (at 10 
 
 
 
g/ml) for the antiglomerular Ab
ELISA. Other antigen-specific ELISAs were performed by coat-
ing Immulon II plates with 10 
 
 
 
g/ml ovalbumin, 10 
 
 
 
g/ml thy-
roglobulin, 10 
 
 
 
g/ml lysozyme, or 1 
 
 
 
g/ml laminin (all obtained
from Sigma-Aldrich).
For all ELISA assays, the background OD was subtracted to
obtain the final ODs. For the binding strengths shown in Table I,
ODs in the respective antigen-specific ELISAs were mapped onto
a semi-quantitative scale. On this scale, “
 
 
 
” and “
 
  
 
” indicate
that the antigen-specific OD values registered by the respective
mAbs (assayed in the linear range of 1–10 
 
 
 
g/ml) were 0.2–0.5,
or 
 
 
 
0.5-fold higher, respectively, compared with the corre-
sponding OD values recorded for “total Ig” assayed in parallel.
ELISAs were repeated twice with each mAb, to ensure reproduc-
ibility of the specificity patterns.
 
DNase-1 Treatment Experiments.
 
ELISA plates were coated
with the desired antigens, and blocked as usual. Antigen-coated
wells were treated with 50 
 
 
 
l of DNase-I (100 
 
 
 
g/ml; Calbio-
chem) in PBS containing 5 mM MgCl
 
2
 
 and 2 mM CaCl
 
2
 
 at 37
 
 
 
C
for 1 h. Sham-treated wells were treated with buffer (PBS) only.
After washing, the test samples were added to the DNase-1 or
sham-treated wells. Alternatively, the test samples (i.e., the Abs)
were treated with DNase-I (final concentration 
 
 
 
 100 
 
 
 
g/ml) in
PBS, containing 5 mM MgCl
 
2
 
 and 2 mM CaCl
 
2
 
 at 37
 
 
 
C for 1 h.
EDTA (final concentration 
 
 
 
 5 mM) was added to terminate the
DNase-I reaction. The total mixture was added to the ELISA 
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plates. The rest of the procedure was the same as for the standard
ELISA as aforementioned. With both treatment approaches, any
residual Ag reactivity was compared with that observed in the
sham-treated controls.
 
In Vivo Pathogenicity Assays.
 
We initially experimented with
the injection of whole hybridoma cells; however, this approach
yielded rather irreproducible results due to variability in the fol-
lowing parameters: (a) variable release of ANAs by the hybridoma
cells in vivo; (b) variable release of apoptotic material by dying
hybridoma cells in vivo; and (c) variable degree of tumorlike ex-
pansion of the hybridoma cells, leading to morbidity and mortal-
ity (unpublished data). Because one of the central goals of this
work was to ascertain the relative pathogenicity of ANAs of dif-
ferent fine specificities, the pathogenicity studies were designed to
minimize or exclude any other factors that may potentially impact
disease outcome or confound data interpretation. In particular,
attention was paid to the following three factors. First, because
injection of whole hybridoma cells resulted in highly variable
outcomes as aforementioned, only defined amounts of concen-
trated or purified mAb was used for the in vivo studies. Second,
urinary protein was measured over 24 h using metabolic cages in-
stead of performing single time point Dipstick tests because the
former approach turns out to be far more quantitative and reli-
able. Third, all outcome measures (proteinuria, blood urea nitro-
gen [BUN], and histology) were performed in a blinded fashion.
2–4-mo-old male NZW mice were used as recipients for the
mAb injection studies. The NZW strain shares 75% of its genome
with the NZM2410 strain, including the 
 
H2
 
 locus (28). Of practi-
cal importance, the NZW strain is free of serum ANAs, and
breeds easily, unlike the NZM2410 derivative. In brief, recipient
mice were administered 10 daily i.p. injections of the respective
mAbs, at a dose of 150 
 
 
 
g/d in a volume of 100 
 
 
 
l, adapting a
well-established protocol (29). All injected mice were killed 24 h
after the last injection on D10, and examined for disease as de-
tailed in the next paragraph. Although this 10-d Ab injection pro-
tocol is sufficient to induce proteinuria and azotemia, it did not in-
flict any significant morphological change in the end organs.
 
Monitoring Renal Disease.
 
All mice challenged with mAbs
were monitored for several parameters of renal disease. 24-h
urine samples were collected from all mice on D0, D4, D7, and
D10 using metabolic cages, with free access to drinking water.
Urinary protein concentration was determined using the Coo-
massie PLUS protein assay kit (Pierce Chemical Co.). Serum
samples were collected on D0 and D10, and BUN was deter-
mined using a urea nitrogen kit (Sigma-Aldrich), following the
manufacturer’s instructions. All surviving animals were killed on
D11, and the kidneys were processed for light microscopy. Renal
histopathology was assessed as described previously (30, 31).
 
Ab Sequencing.
 
Hybridoma cells were lysed in TRIzol
(GIBCO BRL) by repetitive pipetting. 1 ml of TRIzol was used
for 5–10 
 
 
 
 10
 
6
 
 cells. Chloroform was added, followed by vigor-
ous agitation, and incubation at rt for 2–5 min. After centrifuga-
tion, the upper aqueous phase was procured and incubated with
isopropanol at rt for 10 min to precipitate the RNA. The RNA
pellet was centrifuged down, washed with 75% ethanol, air-dried,
and dissolved in 0.1% diethylpyrocarbonate water (Sigma-
Aldrich). RNA concentration and purity were gauged using
OD
 
260/280
 
 absorbance. RT-PCR was performed on total RNA
using a commercially available kit (Promega), following the man-
ufacturer’s instructions. The respective heavy chain (HC) and
light chain (LC) sequences were PCR amplified from the cDNA
using the following sense and antisense primers (IDT-DNA): V
 
H
 
,
5
 
 
 
-AGGT(G/C)(A/C)A(A/G)CTGCAG(G/C)AGTC(A/T)GG-
3
 
 
 
; C
 
 
 
, 5
 
 
 
-CAGGGGGCTCTCGCAGGAGACGAGG-3
 
 
 
; C
 
 
 
,
5
 
 
 
-GGACAGGGATCCAGAGTTCC-3
 
 
 
; V
 
 
 
, 5
 
 
 
-CCAGATG-
TGTGATGACCCAGACTCCA-3
 
 
 
; C
 
 
 
: 5
 
 
 
-GTTGGTGCAG-
CATCAGC-3
 
 
 
; V
 
 
 
1
 
, 5
 
 
 
-TCTCCTGGCTCTCAGCTCAG-3
 
 
 
;
V
 
 
 
2
 
, 5
 
 
 
-GCCATTTCCCAGGCTGTTGTGACTCAGG-3
 
 
 
; V
 
 
 
x
 
,
5
 
 
 
-GAGCTTAAGAAAGATGGAAGCCA-3
 
 
 
; C
 
 
 
1
 
, 5
 
 
 
-CTTC-
AGAGGAAGGTGGAAACAGGGTG-3
 
 
 
; and C
 
 
 
2
 
, 5
 
 
 
-GGT-
GAG(A/T)GTGGGAGTGGACTTGGGC-3
 
 
 
.
PCR was performed over 35 cycles using the following pa-
rameters: 45 s at 94
 
 
 
C, 60 s at 58
 
 
 
C, and 90 s at 72
 
 
 
C. PCR prod-
ucts were gel purified using the QIAEX II gel extraction kit
(QIAGEN), and direct sequenced using either the 5
 
 
 
 or 3
 
 
 
 prim-
ers and the PRISM Ready Reaction Dye Terminator sequencing
kit (Applied Biosystems) on a sequencing machine (model
ABI377; Applied Biosystems). Ambiguous sequences were rese-
quenced. The Taq error rate was estimated to be 
 
 
 
1 in 4,000 nu-
cleotides, based on multiple rounds of sequencing the C
 
 
 
 gene.
All sequences have been deposited into GenBank/EMBL/DDBJ
(accession nos. AY436915-AY437055).
 
Sequence Analysis and Statistics.
 
All Abs in the ANA and non-
ANA databases were “blasted” against the publicly accessible “Ig-
Blast” database of mouse Ig sequences at the National Center for
Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.
gov/igblast) to determine the closest germline gene of origin, and
to identify potential mutations. The CDR position and number-
ing scheme adopted matched that used by the National Center
for Biotechnology Information IgBlast database. The frequencies
of antibody V/J gene usage and the respective frequencies of in-
dividual amino acid residues at each CDR position were com-
pared between the groups using chi-square tests. Where appli-
cable, the Fisher’s exact test was applied. The different CDR
regions were also compared with respect to their mean isoelectric
point (pI) as described previously (25, 32). Intergroup compari-
sons of phenotypes after in vivo Ab injections were also per-
formed using the Student’s 
 
t
 
 test (paired, where appropriate). All
statistical comparisons were performed using SigmaStat (Jandel
Scientific).
 
Online Supplemental Material.
 
Table S1 shows the V-, D-, and
J-gene origins of arginine and lysine residues in the HC CDR3
regions of the ANAs and non-ANAs rescued from the
NZM2410 mice. Indicated also are the orientations of the
D-genes used in the respective CDR3 regions. Table S2 shows
the frequencies of nongermline encoded nucleotides and amino
acid residues in the CDR and framework regions of HC and LC
of the NZM2410-derived ANAs and non-ANAs. Also indicated
are the frequencies of silent and replacement mutations in the re-
spective Ab groups. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20030132/DC1.
 
Results
 
Specificity Profiles of Rescued ANAs.
 
A total of 56 anti-
nuclear Abs (Table I), and 47 nonnuclear Ag-reactive Abs
were rescued from four seropositive NZM2410 mice
(named NZM-A to NZM-D). The rescued ANAs from all
four mice were truly polyclonal, with only a modest degree
of oligoclonal expansion. Within each mouse panel, the
mAbs have been ordered according to their nuclear antigen
specificity profile, as follows (Table I): (a) Abs that reacted
predominantly with histones and/or nucleosomes; (b) Abs
that reacted predominantly with ssDNA; (c) Abs that re-
acted with dsDNA, but not histones; and (d) Abs that re- 
Monoclonal ANAs from NZM2410 Mice
 
384
acted with all of the aforementioned Ags, including DNA
and histones.
This spread of nuclear antigen fine specificity is illus-
trated by mAbs rescued from the NZM-B mouse. As evi-
dent from Table I, the top quarter of all rescued Abs from
this mouse represented antihistone Abs. It is not surprising
that this category of Abs also reacted with histone–DNA
complexes and nucleosomes because these composite Ags
also bear histone epitopes. There was a nearly perfect cor-
relation between histone/DNA reactivity and specificity
for nucleosomes, with a few exceptions as noted in paren-
theses in Table I. The second quarter of this panel reacted
predominantly with ssDNA; most of these Abs did not
bind histone–DNA complexes or nucleosomes, presumably
because the DNA in these complexes is double stranded in
conformation. The third quarter of this panel reacted with
dsDNA (and hence with histone–DNA complexes and nu-
cleosomes), but not with DNA-free histones. Finally, the
 
Table I.
 
Specificities of Antinuclear mAbs Rescued from 
NZM2410 Mice
 
Mice mAb
 
a
 
Isotype Histone
Histone/
DNA
 
b
 
dsDNA ssDNA
NZM-A ZA3A8 IgM
 
 
 
c
 
  
 
––
ZA4E6 IgM
 
  
 
––
ZA7F8 IgM
 
     
 
––
ZA1B11 IgM –
 
 
 
–
 
 
 
ZA6A8 IgM – – –
 
 
 
ZA5E11 IgM –
 
       
 
ZA8C4 IgM –
 
   
 
ZA7H10 (b) IgG2a –
 
        
 
ZA1E4 IgM
 
   –
ZA1E5 (a) IgM          
ZA2D8 (a) IgM       –
ZA6C10 IgM   ( )     
ZA3F7 (b) IgG2a             
NZM-B ZB7D12 IgM     ––
ZB7E10 IgG2a       ––
ZB2C11 (c) IgM       ––
ZB4A12 (e) IgM       ––
ZB7B1 (e) IgM       ––
ZB4H7 IgM   –––
ZB7F11 (d) IgM       ––
ZB10B6 IgM –   ––
ZB5G11 IgM   ––  
ZB9A6 IgM   ––  
ZB1A7 IgG3 –   –   
ZB2E5 IgM – – –  
ZB2F12 IgM – – –  
ZB5D2 IgM – – –  
ZB5F3 IgM – – –  
ZB9G6 IgM – – –  
ZB2G14 IgG2a –       –
ZB5D3 IgG2a –       –
ZB2F10 IgM –        
ZB2G10 IgM – ( )     
ZB3C7 IgM –         
ZB8A7 IgM         –
ZB2C1 IgG2b        –
ZB10C9 IgM     
ZB4E2 (c) IgM        
ZB5B4 IgM          
ZB2D7 (d) IgM          
ZB1D9 IgM    ( )     
ZB4D8 (d) IgG1            
ZB7D7 IgM            
ZB1B11 IgG2a            
NZM-C ZCE1 IgM –    ––
ZCH1 IgM – – –  
ZCA3 IgG1 –         
ZCF4 IgM           
ZCB1 IgM         
NZM-D ZDD2 IgM       ––
ZDB4 IgG2b –    ––
ZDC1 IgM –         
ZDC3 IgM     –  
ZDA3 (f) IgM      –   
ZDB2 (f) IgM      –   
ZDD1 IgG2a –         
aAll nuclear antigen-reactive monoclonal hybridomas rescued from the
four NZM2410 mice are listed, ordered according to their antigen-
binding profile. The first two letters of each mAb refer to the
NZM2410 mouse of origin. For example, “ZA” refers to the mouse
NZM-A. The clonal relationships observed among the rescued hybrid-
omas are indicated in parentheses. All mAbs listed demonstrated anti-
nuclear fluorescence on Hep-2 cells, with the exception of ZB9G6 and
ZB4E2 (in italics).
bThere was a near-perfect concordance between the results of the anti-
nucleosome ELISA and the antihistone/DNA ELISA, with a few ex-
ceptions shown in parentheses.
cAntigen reactivity was tested by ELISA. All OD values in the respec-
tive antigen-specific ELISAs were mapped onto a semi-quantitative
scale. On this scale, “ ” and “  ” indicate that the antigen-specific
OD values registered by the respective mAbs (assayed in the linear
range of 1–10  g/ml) were 0.2–0.5, or  0.5-fold higher, respectively,
compared with the corresponding OD values recorded for “total Ig”
assayed in parallel.
Table I. Specificities of Antinuclear mAbs Rescued from 
NZM2410 Mice
Mice mAba Isotype Histone
Histone/
DNAb dsDNA ssDNA
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last quarter of this panel showed reactivity to all of the
tested antigens, including DNA and histones.
With respect to the latter specificity, potential dual re-
activity to both histones and DNA seemed somewhat un-
likely given the diametrically opposite polarities of these
two antigens. One possibility was that the apparent reac-
tivity to histones and/or DNA was mediated by nucleoso-
mal Ags (originating, for example, from apoptotic hybrid-
oma cells in culture) that were bound to the Ag-binding
grooves of these mAbs; these moieties may have served as
antigenic bridges facilitating contact with the DNA and/
or histones coated on the ELISA plates. Thus, it was cer-
tainly conceivable that an anti-DNA or antinucleosome
Ab might be masquerading as an antihistone Ab (or vice
versa) through this mechanism. To ascertain if this phe-
nomenon was indeed responsible for the observed ds-
DNA/histone dual reactivity, six representative dual-reac-
tive ANAs were subjected to DNase-I treatment to digest
away any bound nucleosomal material before reassaying
their reactivity to dsDNA and/or histones. DNase-1 treat-
ment of the Ab abrogated the ability of most of these
“dual-reactive” Abs to bind histones (Fig. 1), but not to
dsDNA (not depicted), suggesting that a substantial frac-
tion of the apparent antihistone reactivity in the sera of
these mice may be attributed to dsDNA-specific Abs. In-
terestingly,  10–20% of the mAbs appeared to retain a
certain degree of histone reactivity despite DNase-1 treat-
ment of both the Ab and the antigenic substrate used for
ELISA. It is currently unclear if these few clones repre-
sented true histone/DNA dual-reactive Abs, or whether
the observed reactivity pattern was due to residual,
DNase-1–resistant, nucleosomal fragments tightly bound
within the Ag-binding pockets of these Abs.
Nephrophilicity of Rescued Monoclonal Antibodies. In addi-
tion to being dsDNA reactive, sera from lupus mice are well
recognized to be highly nephrophilic. To examine this at
Figure 1. Nuclear antigenic bridges facilitate histone binding by anti-
DNA Abs. Six representative anti-dsDNA/antihistone dual-binding Abs
were subjected to DNase-I or sham treatment as detailed in Materials and
Methods. Likewise, the histone substrate (i.e., “Antigen”) was also sub-
jected to DNase-I or sham treatment. All Abs were tested for histone
reactivity within the same ELISA plates. Horizontal bars represent the
mean histone reactivity within each treatment group. The depicted p-values
represent the result of comparing each group with the sham-treated (Ab
and Ag) control. All DNase-I–treated Abs retained dsDNA-binding after
treatment (not depicted).
Figure 2. Glomerular reactivity of NZM2410-derived ANAs. (A) All
the NZM2410-derived ANAs listed in Table I were tested for their reac-
tivity to glomerular substrate as detailed in Materials and Methods. The
56 mAbs studied may be categorized into four groups according to their
predominant Ag specificity pattern: anti-ssDNA Abs (n   11), antihistone/
nucleosome Abs (n   14), nonhistone binding anti-dsDNA Abs (n   10),
and Abs that reacted with both histones and DNA (n   21). In the com-
posite bar graphs, the percentages of Abs within each group that tested
positive for nephrophilicity are shown. (  and   ) The glomerular antigen-
specific reactivity (OD) of the respective mAbs (assayed in the linear
range of 1–10  g/ml) was 0.2–0.5, or  0.5-fold higher, respectively,
compared with the corresponding OD values recorded for “total Ig,” assayed
in parallel. The percentage of dsDNA/histone dual binder Abs that also
reacted with glomerular substrate was significantly higher than the corre-
sponding percentages observed among anti-ssDNA ANAs (P   0.002),
antihistone/nucleosome Abs (P   0.03), and the nonhistone-binding
anti-dsDNA Abs (P   0.013), as determined using the Fisher’s exact test.
(B) Five representative antiglomerular Abs (that also reacted with dsDNA)
were subjected to DNase-I or sham treatment as detailed in Materials and
Methods. Likewise, the glomerular substrate (i.e., Antigen) was also
subjected to DNase-I or sham treatment. All Abs were tested for glomerular
reactivity within the same ELISA plates. Horizontal bars represent the
mean glomerular reactivity within each treatment group. The depicted
p-values represent the result of comparing each group with the sham-
treated (Ab and Ag) control.Monoclonal ANAs from NZM2410 Mice 386
the monoclonal level, the panel of antibodies listed in Table
I was tested for glomerular reactivity by ELISA. A substan-
tial fraction of these mAbs exhibited “nephrophilicity,”
with an interesting relationship to their nuclear antigen re-
activity profile. As depicted in Fig. 2,  80% of the histone/
DNA dual binders listed in Table I had the capacity to bind
glomerular substrate as well. In contrast, only  20–30% of
the mAbs in the other ANA specificity categories, and none
of the non-ANAs exhibited glomerular reactivity. Glomer-
ular binding observed in these in vitro assays could have
been potentially mediated by one of two mechanisms. First,
this could represent direct binding of the mAb to the glo-
merular substrate. Alternatively, this might not represent
bona fide glomerular reactivity, but an apparent reactivity
that is mediated by nucleosomal antigenic bridges, as afore-
mentioned for histone binding. As observed for the histone
reactivity experiments, it is interesting to note that a sub-
stantial fraction of the glomerular reactivity was abrogated
by DNase-1 treatment of the Abs; only a minor fraction of
the antiglomerular reactivity observed represented true
DNA/glomerular dual reactivity (Fig. 2 B). Thus, together
with the data in Table I and Fig. 1, a substantial fraction of
the monoclonal ANAs rescued from NZM2410 mice dem-
onstrated apparent “polyreactivity” to DNA, histones, and
glomerular substrate as a consequence of Ab-bound nuclear
material serving as antigenic bridges. However, these mAbs
were not truly “polyreactive,” because they lacked reactiv-
ity to several nonnuclear antigens tested, including ovalbu-
min, thyroglobulin, and lysozyme (unpublished data).
Pathogenic Potential of Rescued IgG Monoclonal Antibodies.
Next, we gauged the in vivo pathogenicity of the IgM and
IgG mAbs rescued from the NZM2410 mice. To ascertain
if there was any relationship between the antigen reactivity
profile of an Ab and its pathogenic potential, we first tested
protein A purified IgG ANAs drawn from four different
specificity groups as follows: (a) IgG non-ANAs that failed
to bind any of the tested nuclear antigens or glomerular
substrate; (b) IgG antinucleosome ANAs that bound his-
tone–DNA complexes and nucleosomes, but not histone-
free dsDNA; (c) IgG anti-dsDNA Abs that did not bind
glomerular substrate; and (d) IgG ANAs that bound ds-
DNA as well as glomerular substrate.
As evident from Fig. 3 A, uninjected NZW mice typi-
cally excreted 0.4–1.0 mg urinary protein daily, with occa-
sional mice excreting  1 mg/d. Clearly, the control non-
ANA Ab as well as the IgG ANAs with reactivity to
histone–DNA nucleosomal complexes and/or ssDNA (but
not dsDNA) did not compromise renal function. In con-
trast, dsDNA-reactive IgG ANAs that lacked glomerular
reactivity (i.e., ZB5D3 and ZA7H10) caused significantly
increased proteinuria on D10, in the range of 1–1.5 mg/d.
Interestingly, with both the histone/DNA–reactive Abs
(ZDB4 and ZB1A7) and the dsDNA-reactive Abs (ZB5D3
and ZA7H10), concomitant reactivity to ssDNA did not
affect the pathogenic potential of these Abs.
Most remarkably, IgG anti-dsDNA Abs with glomerular
reactivity (i.e., ZB4D8 and ZB1B11) precipitated signifi-
cant proteinuria (P   0.0003) in the range of 1.5–2.5 mg/d
on D10. In particular, the 24-h urinary protein levels in
mice injected with IgG glomerular-binding anti-dsDNA
ANAs (n   10; mean   1.88 mg/24-h) were significantly
higher than the corresponding values in mice injected with
IgG anti-dsDNA Abs (n   10; mean   1.30 mg/24-h;
P   0.003) on D10. Graphed in Fig. 3 B are the 24-h
urine protein excretion levels recorded in the 10 mice in-
jected with the IgG glomerular-binding anti-dsDNA ANAs
(i.e., five mice injected with ZB4D8 and five mice injected
with ZB1B11), as measured on D0, D3, D7, and D10.
Figure 3. Renal pathogenicity of NZM2410-derived IgG ANAs.
(A) Seven representative NZM2410-derived IgG mAbs were tested for
in vivo pathogenicity as detailed in Materials and Methods. Although
ZB4D8, ZDB4, and ZB1A7 were IgG1, IgG2b, and IgG3 in isotype,
respectively, all other Abs were IgG2a in isotype. The specificity profiles
of these Abs that have been tabulated below the figure were obtained
from Table I. It should be noted that “ ” in this figure simply indicates
that the mAb reacts with the respective Ag, independent of the strength
of reactivity. Both the beginning (D0, white dots), and ending (D10,
black dots) 24-h urine protein levels (measured using metabolic cages) are
depicted. Where the D10 proteinuria levels were found to be significantly
higher than the corresponding D0 levels (using the Student’s t test), the
p-values are listed. (B) The 24-h urine protein excretion profiles of the
10 mice injected with IgG anti-dsDNA/glomerular dual binding Abs,
ZB1B11 and ZB4D8, are depicted. 24-h urine protein measurements
were performed on D0, D3, D7, and D10 after mAb administration. (C) The
BUN levels measured on D0 and D10 after administration of the dsDNA/
glomerular dual binding Abs, ZB4D8 and ZB1B11, are depicted. Depicted
below each column of dots are the p-values calculated when the D0 and
D10 BUN values were compared (using the Student’s t test), and found
to be significantly different. The dotted line refers to the mean D10 BUN
level noted in all the other experimental groups of mice, combined.Liang et al. 387
Overall, these mice exhibited a progressive near-linear de-
terioration in renal function (as gauged by proteinuria) in
a cumulative dose-dependent fashion. In addition, these
mice had significantly higher BUN levels at the conclusion
of the experiment, in contrast with the mice in the other
treatment groups (Fig. 3 C).
Pathogenic Potential of Rescued IgM Monoclonal Antibodies.
Next, a panel of nine IgM mAbs was selected for pathoge-
nicity testing. As aforementioned, uninjected NZW mice
excreted urinary protein of  1 mg/d. Clearly, IgM non-
ANAs and Abs with reactivity restricted to histone–DNA
nucleosomal complexes and/or ssDNA (but not dsDNA)
did not compromise renal function significantly (Fig. 4 A).
In contrast with the findings with the IgG ANAs, IgM Abs
that were discordant in their reactivity patterns to dsDNA
and glomeruli (e.g., ZA7F8, ZDC3, and ZA5E11) did not
appear to be pathogenic. However, IgM Abs that had the
potential to bind all of the aforementioned Ags, including
dsDNA and glomerular substrate, were clearly pathogenic,
leading to the excretion of 1–1.6 mg/d urinary protein
(Fig. 4 A). Indeed, the D10 24-h urinary protein levels in
the mice injected with these apparently polyreactive IgM
Abs (n    13; mean   1.3 mg/24-h) were significantly
higher than the D10 24-h urinary protein excretion levels
observed in all other experimental groups combined (n  
30; mean   0.9 mg/24-h; P   0.0006). Finally, the mice
in two of the three groups receiving dsDNA/glomeruli
dual-reactive IgM Abs exhibited significantly elevated
BUN levels at the conclusion of the experiments (Fig. 4 B).
Immunoglobulin Gene Usage by NZM2410-derived ANAs
and non-ANAs. A second goal of this work was to eluci-
date the molecular signatures of ANAs. To achieve this, we
compared the molecular profiles of the aforementioned
NZM2410-derived ANAs with those of nonnuclear Ag-
reactive Abs rescued from the same mice. HC and LC se-
quence information was successfully retrieved from 40 out
of the 47 hybrids that exhibited no reactivity to ssDNA, ds-
DNA, histones, histone–DNA nucleosomal complexes, or
to the glomerular substrate. These non-ANA Abs were also
largely IgM in isotype, with most of the remainder being
predominantly IgG2a in isotype (unpublished data). Thus,
the overall isotype distribution was similar to that observed
among the ANAs (Table I). For further molecular compar-
ison of these non-ANAs with the aforementioned ANA
panel, all clonal families were represented by one isolate
each (to avoid any potential skewing of the data due to the
expanded clones). All non-ANA mAbs sequenced were
clonally independent, as indicated by their distinct HC
CDR3 sequences. For each of the six clonal trees in the
ANA panel (Table I, letters in parentheses), the most mu-
tated member was retained for further comparative analysis.
This reduced the sample size of ANAs to 49. Although the
depicted data pertain only to datasets where the clonal sib-
lings have been removed, inclusion of all clonal siblings did
not impact the findings, owing perhaps to the modest de-
gree of clonality seen among these mAbs (Table I).
As shown in Table II, Abs from both panels exhibited a
fairly similar VH utilization profile, with VH1/J558 pre-
dominating. Interestingly, there was significant overuti-
lization of VH5/7183 among the ANAs (P   0.05), with
this family being represented by at least six different germ-
line genes (unpublished data). In particular, two out of
these six VH5 germline genes, VH283 and VH76–1BG,
together accounted for more than half of all the VH5-
Figure 4. Renal pathogenicity of NZM2410-derived
IgM ANAs. (A) Nine representative NZM2410-derived
IgM mAbs were tested for in vivo pathogenicity as detailed
in Materials and Methods. The specificity profiles of these
Abs that have been tabulated below the figure were obtained
from Table I. It should be noted that “ ” in this figure
simply indicates that the mAb does react with the respective
Ag, independent of the strength of reactivity. Both the
beginning (D0, white dots) and ending (D10, black dots)
24-h urine protein levels (measured using metabolic cages)
are depicted. Where the D10 proteinuria levels were
found to be significantly higher than the corresponding D0
levels (using the Student’s t test), the p-values are listed.
(B) Depicted below are the BUN levels measured on D0
and D10 after Ab administration. Depicted below each
column of dots are the p-values (calculated using the Student’s
t test), where the D0 and D10 BUN values were compared
and found to be significantly different.Monoclonal ANAs from NZM2410 Mice 388
encoded ANAs rescued. With respect to the Vk utilization
profile, the Vk1 and Vk4/5 families were the most fre-
quently used in both the Ab panels, as noted for other
ANAs and non-ANAs described previously (26). No fur-
ther differences were noted when the nuclear antigen fine
specificities of the ANAs were factored in. In addition, no
preferential copairing of any particular VH or Vk germline
genes were noted that distinguished ANAs from non-
ANAs (unpublished data).
Fig. 5 depicts the Jk utilization profiles of the
NZM2410-derived ANAs and non-ANAs, as well as those
of ANAs and non-ANAs described previously (26). Al-
though the ANAs and non-ANAs derived from the
NZM2410 mice did not differ significantly in terms of
their Jk usage, both these groups of Abs had significantly
higher Jk5 utilization frequencies. Therefore, the Jk5:Jk1
ratios in the NZM2410-derived ANAs (ratio   1.2), and
non-ANAs (ratio   1.1), were significantly higher (P  
0.013 and P   0.006, respectively) compared with the
ANAs (ratio   0.6) and non-ANAs (ratio   0.4) drawn
from the National Center for Biotechnology Information/
GenBank/EMBL/DDBJ databases. Factoring in the nu-
clear antigen fine specificities of the ANAs did not reveal
any further differences. Thus, it is tempting to posit that
these NZM2410-derived Abs (i.e., both the ANAs as well
as the non-ANAs) may largely be the end product of a vig-
orous receptor-editing program at the LC locus. Neverthe-
less, one cannot exclude the possibility that other, yet to be
defined, immunogenetic factors may be influencing Jk re-
combination in the NZM2410 genetic background.
CDR Lengths and Cationicity of NZM2410-derived
ANAs. The CDR1, CDR2, and CDR3 sequences of
NZM2410-derived ANA HC and LC are listed in Tables
III and IV, respectively. The HC CDR3 lengths were not
significantly different between these two groups of Abs
(9.5 residues among the ANAs vs. 9.9 residues among the
non-ANAs; P   0.05). Likewise, no differences were
noted in LC CDR1 lengths (13.5 residues vs. 12.6; P  
0.05). Previous papers comparing ANAs and non-ANAs
have observed the CDR3 regions of ANA HC to be sig-
nificantly more cationic (for reviews see references 20–25).
In resonance with those observations, the mean pI value
(averaged across the first six residues) of HC CDR3 was
significantly higher among the NZM2410-derived ANAs
compared with the non-ANAs (6.18 vs. 5.76; P   0.006;
Fig. 6). Interestingly, the CDR3 regions of ANAs demon-
strated alternating peaks of significant cationicity at posi-
tions H96 (P   0.05), H98 (P   0.01), and H100 (P  
0.05), compared with the non-ANAs. The intervening po-
sitions at H95, H97, and H99 appeared to be uniformly
neutral (with mean pI values hovering just below 6). In
contrast, the non-ANAs were relatively neutral at most of
these CDR3 positions and significantly more anionic at
H98 (Fig. 6).
Residue Usage Differences in ANAs versus non-ANAs.
Consistent with the pI profile differences portrayed in Fig.
6, NZM2410-derived ANAs exhibited significantly more
“R” residues (9.4 vs. 3.8%, representing the mean percent-
ages averaged across H95-H100a; P   0.02) and signifi-
cantly less “D” residues (5.8 vs. 10.5%; P   0.05) in their
HC CDR3 regions, compared with the non-ANAs. As is
clear from Fig. 7 A, the NZM2410-derived ANAs exhib-
ited peak usage of “R/K” residues (especially “R”) at the
alternating positions, H96, H98, and H100 (as well as
Table II. VH and Vk Family Usage by ANAs and Non-ANAs 
Derived from NZM2410 Mice
ANAsa
(n   49)
non-ANAs
(n   40)
%%
VH family
VH1(J558) 55.1 75.0
VH2(Q52) 12.2 15.0
VH3(36-60) 2.0 0.0
VH4(X24) 0.0 0.0
VH5(7183) 26.5b 7.5
VH6(J606) 0.0 0.0
VH7(S107) 4.1 2.5
VH8(3609) 0.0 0.0
VH9(VGAM3.8) 0.0 0.0
VH10(VH10) 0.0 0.0
VH11(VH11) 0.0 0.0
VH12(VH12) 0.0 0.0
VH13(3609N) 0.0 0.0
VH14(SM7) 0.0 0.0
VH15(VH15) 0.0 0.0
Vk family
Vk1 17.0 16.4
Vk2 8.5 3.7
Vk4/5 19.2 23.6
Vk8 4.3 5.5
Vk9/10 8.5 3.6
Vk12/13 6.4 3.6
Vk19/28 6.4 5.5
Vk20 0.0 1.8
Vk21 10.6 7.3
Vk23 10.6 14.6
Vk24/25 4.3 1.8
Vk32 0.0 1.8
Vk33/34 0.0 0.0
Vk38 0.0 5.5
VkRF 4.3 5.5
aAll tabulated Abs are clonally independent. The antigenic fine specifities
of the ANAs are listed in Table I. Of the 49 ANA hybridomas sequenced,
3 expressed V-  LC; therefore, the depicted percentages pertain to LC
sequence data obtained from 46 ANA hybrids.
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H100a). In the intervening positions, H95, H97, and H99,
the frequencies of R/K residues were outweighed by the
corresponding frequencies of “D/E” residues. In contrast
with the ANAs, the non-ANAs exhibited peak usage of
anionic D/E residues (especially “D”) at the same alternat-
ing positions, H96, H98, and H100. These reciprocal
charge patterns at H96–H98 are highlighted using arrow-
heads in Fig. 7 A; these findings resonate well with the pI
profile differences shown in Fig. 6.
Although the aforementioned charge motif was evident
when all ANAs were examined in aggregate, no single
ANA exhibited cationic residues at all three of the impli-
cated CDR3 positions. However, several isolates demon-
strated pairs of cationic residues at the alternating positions,
H98 and H100, or H100 and H100b, including 3 out of 17
exclusive nucleosome binders, and 5 out of 28 dsDNA
binders. Particularly impressive were the HC CDR3 re-
gions of the dsDNA-reactive ANA, ZB2G14, which exhib-
ited cationic residues at the alternating positions, H98,
H100, and H100b. Although it would be important to as-
certain if and how the anti-dsDNA/glomerular antibodies
compared with the antinucleosome Abs, with respect to
these signatures, no further differences were noted when the
Abs were stratified by fine specificity (unpublished data).
Next, we analyzed the ANAs and the non-ANAs to
gauge the molecular origins of the increased R/K residues
in HC CDR3. Although the NZM2410-derived ANAs
exhibited higher frequencies of D:D fusions (a feature that
has been proposed by others as being an important contrib-
utor of CDR3 R residues), these differences were not sta-
tistically significant. As illustrated in Table S1 (available at
http://www.jem.org/cgi/content/full/jem.20030132/DC1),
the NZM2410-derived ANAs and non-ANAs did not dif-
fer in the genetic origins of their CDR3 R/K residues.
Thus, in both groups of Abs, R/K residues at H95 were
predominantly the result of V–D fusion (with N inser-
tions), whereas R/K residues at H99–H100a were either
D-gene encoded, or were the result of D–J recombination
(with N insertions). Likewise, ANAs and non-ANAs did
not differ in the D-gene reading frames they preferentially
used, to encode the R/K residues (unpublished data).
Thus, it is reasonable to posit that, although the molecular
mechanisms that can potentially give rise to R/K residues
Figure 5. Jk usage frequen-
cies among ANAs and non-
ANAs. Indicated are the LC Jk
usage frequencies of NZM2410-
derived ANAs (n    46),
NZM2410-derived non-ANAs
(n   40), previously documented
ANAs (from NCBI/GenBank/
EMBL/DDBJ;  n    264), and
non-ANAs (from NCBI/Gen-
Bank/EMBL/DDBJ; n   145).
The NCBI collection of ANAs
and non-ANAs represents two
new databases of LC sequences
recently constructed and analyzed.
The control ANAs represent 264
previously documented ANA
LC sequences, drawn from 35
primary works, from which clonal
replicates have been removed;
they consisted of 139 anti-ss-
DNA, 103 anti-dsDNA, and 22
antinucleosome Abs (26). The NCBI/GenBank/EMBL/DDBJ “non-ANAs” represent the LC sequences of 145 non-ANAs (with known antigen spec-
ificities) drawn from the NCBI/GenBank/EMBL/DDBJ database, with no overlapping target antigen specificities. Importantly, all clonal replicates have
been removed from all four of the databases studied, so as to minimize any potential bias due to multi-member clones. The frequencies of Jk5 among the
NZM2410-derived ANAs and non-ANAs were significantly higher (P   0.013 and P   0.009, respectively) when compared with the corresponding
frequencies observed among the NCBI-derived ANAs and non-ANAs.
Figure 6. pI profiles across HC CDR3 regions of NZM2410-derived
ANAs and non-ANAs. The mean pI value (isoelectric point) at each HC
CDR3 position (from H95 to H100a) was calculated as detailed in Materials
and Methods. As evident from Table III, few Abs had CDR3 residues
beyond position H100a. The mean pI values observed among the
NZM2410-derived ANAs (n   49) and non-ANAs (n   40) are plotted.
Importantly, all clonal replicates have been removed from both databases.
The pI values of the ANAs were systematically compared with the pI
values of the non-ANAs at each indicated CDR position using the Student’s
t test (*, P   0.05; **, P   0.01).Monoclonal ANAs from NZM2410 Mice 390
Table III. Immunoglobulin Heavy Chain Usage by NZM2410-derived ANAs 
VH gene usageb CDR1c CDR2 CDR3
Mice mAba Family GL Jh 31 32 33 34 35 50 51 52 a 53 54 55 56 57 58 59 60 61 62 63 64 65 95 96 97 98 99 100 a b c d e f i j k 101 102
NZM-A ZA3A8 S107 V11 1 D Y Y M S L I R N N G Y T T E Y S A S A K G E P Y G S S Y D – – – – – – – – –
ZA4E6 7183 Vh283 2 N Y A M S T I S S G G S Y T Y Y P D S V K G P L T G Y – – – – – – – – Y F D Y
 ZA7F8 7183 Vh283 3 N Y A M S T I D D G G S Y I S Y P D S V K G P N Y G S S Y L – – – – – – F A Y
ZA1B11 7183 7183.22b 4 D Y G M H Y I S S G S S T I Y Y A D T V K G D L L W L R R R – – – – Y A M D Y
ZA6A8 36-60 36-60 2 S D Y M N S I S Y – S G S T Y Y N P S L R S S W A Y – – – – – – – – – Y F D Y
 ZA5E11 J558 J558.c 1 S Y W M H E I N P S N G G T N Y N E K F K S G R – – – – – – – – – – W Y F D V
 ZA8C4 J558 V130 2 D D Y M H W I D P E N G D T E Y A S K F Q G P Y G – – – – – – – – – – – – – –
 ZA7H10  (b) J558 V23 2 S Y W M H Y I N P S S G Y T E Y N Q K F K D Y Y F G S S Y – – – – – – Y F D Y
ZA1E4 J558 V102 1 G Y N W N N I N P Y Y G S T S Y N Q K F K G G N – – – – – – – – – – W Y F D V
ZA1E5 (a) J558 V23 3 R Y W M H E I N P S N G G T N F N E K F K S G A N W D E W R – – – – – – F A Y
ZA2D8 (a) J558 V23 3 R Y W M H E I N P S N G G S N S N E N F K N G A N W D E W R – – – – – – F A Y
ZA6C10 7183 Vh76-1BG 2 N Y A M S T I S S G G S Y T Y Y P D S V K G H G A G T – – – – – – – – Y F D Y
ZA3F7 (b) J558 V23 2 R Y W M H Y I N P S S G Y T E Y N Q K F K D Y Y Y G T I Y – – – – – – Y F D S
NZM-B ZB7D12 7183 VH283 3 S Y G M S T I S G G G G N T Y Y P Q S V K G Y K A A R A T Y – – – – – W F A Y
ZB7E10 Q52 Vox-1 3 S Y G V D V I W G – G G N T N Y N S A F K S D R G Y S H P – – – – – – – F A Y
ZB2C11 (c) J558 10B10.S 2 G Y N M H Y I D P Y N G A T T Y N Q K F K G G R P P A – – – – – – – – – – – –
ZB4A12 (e) Q52 Vox1 3 S Y G V D V I W G – G G S T N Y N S V F S S D R G Y S Y P – – – – – – – F A Y
ZB7B1 (e) Q52 Vox1 3 S Y G V D V I W G – G G S T N Y N S V L K S D R G Y S Y P – – – – – – – F A Y
ZB4H7 7183 7183.14 1 N Y D M S T I S S G G S Y T Y Y P D S V K G H G S S L – – – – – – – W Y F D V
 ZB7F11  (d) J558 V23 2 T Y W M H Y I N P S S G Y A D Y I Q K F K D R E G R L R R G Y – – – – Y F D Y
ZB10B6 J558 V6 1 S Y W M H N I Y P G S S S T N Y N E K F K S G A R A T H – – – – – – W Y S D V
ZB5G11 J558 J558.1 4 D Y Y M D Y I Y P N N G G T S Y N Q K F K G P G D W G – – – – – – – – A M D Y
ZB9A6 J558 10B10.S 2 G Y N M N N I N P Y Y G S T S Y N Q K F K G P Y G Y D G G Y – – – – – Y F D Y
 ZB1A7 J558 MVARG2 2 N Y G I S E I Y P R S G N T Y Y N E K F K G E G R T V Y – – – – – – – Y F D Y
ZB2E5 J558 J558.c 3 S Y W M H Y I N P S S A Y T E Y N Q K F K D W G – – – – – – – – – – – – F A Y
ZB2F12 J558 MVARG2 2 N Y G I S E I Y P R S G N T F Y N E K F K G R I G N – – – – – – – – – – – – Y
ZB5D2 Q52 Vox-1 1 S Y A I S V I W T – G G G T N Y N S A L K S K G G N – – – – – – – – Y W F D V
ZB5F3 J558 VMU3.2 3 D Y Y M H E I Y P G S G N T Y Y N E K F K G D S Y Y G S C S – – – – – – F A Y
ZB9G6 J558 119.12 3 G Y Y M H E I N P S T V S T T Y N Q N F K A E G D W P – – – – – – – – – F A Y
ZB2G14 J558 V3 4 S Y W M H K I D P S D S E T H Y N Q K F K D S A L R L R T K P N E P – – M D Y
 ZB5D3 S107 V11 1 D Y Y M S L I R N N G Y T T D Y R A S V K G D S P L L R L R G – – – – Y F D Y
ZB2F10 J558 V6 1 S Y W M H K I D P S D S E T H Y N Q K F K D R G P P Y – – – – – – – W Y F D V
ZB2G10 J558 VMU3.2 3 S Y W M N R I Y P G D G D T N Y N G K F K G G H S S G Y S – – – – – – W F A Y
ZB3C7 Q52 Vox-1 1 S Y G V H V I W S – G G S T D Y N A A F I S L G – – – – – – – – – – – Y F D V
ZB8A7 7183 VH76-1BG 3 N Y A M S T I S S G G T Y T F Y P D S V K G H R D G Y S – – – – – – – W F A Y
ZB2C1 Q52 Vox1 1 S Y T I N V I W T – G G G T N Y N S A L K S I S P L L R L R N – – – W Y F D V
ZB10C9 J558 VMU3.2 4 D Y Y I N W I Y P G S G N T K Y N E K F K G W V G S P – – – – – – – Y A M D Y
ZB4E2 (c) J558 10B10.S 2 G Y N M H Y I D P Y N G A T T Y N Q K F K G G R P P A – – – – – – – – – – – –
ZB5B4 J558 V23 3 R Y W M H E I N P S N Q Q T N F N E K F K S G A N W D E W R – – – – – – F A Y
ZB2D7 (d) J558 V23 2 S Y W M H Y I N P S S G Y N D Y N Q K F K D R E G R L R R G Y – – – – Y F D Y
ZB1D9 Q52 Vox-1 3 S Y A I T V I W T – G G G T N Y N S A L K S G L Y Y G Y E A – – – – – W F A Y
 ZB4D8  (d) J558 V23 2 T Y W M H Y I N P S S G Y N D Y N Q K F K D R E G R F R R G K – – – – Y F D Y
 ZB7D7 J558 119.12 4 G Y Y M H E I N P R T G G T S Y N Q K F K A G D L D – – – – – – – – – A M D Y
 ZB1B11 7183 7183.3b 3 N Y A M S Y I S S G G Y S T Y Y P D S V K G V V Y G E A – – – – – – – – – A Y
NZM-C ZCE1 J558 J558.1 2 D Y Y M N R V N P S N G G T S Y N Q K F K G A P L P Y – – – – – – – – Y F D Y
ZCH1 J558 V102 3 T Y W I H E I D P S D T Y T Y Y N Q K F K G W G D G P – – – – – – – – – F A Y
ZCA3 7183 7183.3b 3 N Y A M S F I S S G G D N T Y Y P D N V K G P N Y V R S Y G – – – – – W F A Y
 ZCF4 J558 V130 3 D D Y I H W I D P E N G D T E Y A S K F Q G P Y G Y D L G R – – – – – – F A Y
ZCB1 7183 VH76-1BG 3 N Y A M G T I S S G G I Y T Y Y P Q S V K G L G L S S – – – – – – – – – F A Y
NZM-D ZDD2 J558 V130 3 D D Y L H W I D P E N G D T E Y A S K F Q G P L G R G – – – – – – – – – F A Y
 ZDB4 J558 VMU3.2 2 S Y W M H R I Y P R N G D A N Y N G E F K G P L L R L R G – – – – – – Y F D Y
 ZDC1 J558 V130 3 D Y Y M H W I D P A N G D T E Y A S K F Q G H Y Y G S T – – – – – – – W F A Y
 ZDC3 J558 V23 1 S Y V M H Y I N P Y N D G T K Y N E K F K G D T T G S S S – – – – – W Y F D V
ZDA3 (f) 7183 7183.9 3 N Y A M S T I S S G G S Y T Y Y P D S V K G Q T Y G S S Y G – – – – – – F A Y
ZDB2 (f) 7183 7183.9 3 N Y A M S T I S S G G S Y T Y Y P D S V K G Q T Y G S S Y G – – – – – – F A Y
ZDD1 7183 VH283 3 N Y A M S Y I S S G G G I T Y Y P D S L K G G T G T G – – – – – – – – – F A Y
aAll mAbs are listed as ordered in Table I. Clonal membership is indicated using letters in parentheses.
bVH family and germline (GL) usage for each mAb are depicted.
cAll CDR residues are shown. H52b and H52c have been omitted because only two Abs had residues at these positions.Liang et al. 391
Table IV. Immunoglobulin Light Chain Usage by NZM2410-derived ANAs
V-  usageb CDR1c CDR2 CDR3
Mice mAba Family GL Jk 24 25 26 27 a b c d e f 28 29 30 31 32 33 34 50 51 52 53 54 55 56 89 90 91 92 93 94 95 96 97
NZM-A ZA3A8 Vk9/10 cp9 1 R A S Q G I S N – – – – – – Y L N Y T S S L H S Q Q Y S K L P P T
ZA4E6 Vk23 23-39 5 R A S Q S I S D – – – – – – Y L H Y A S Q S I S Q N G H S F P P T
 ZA7F8 Vk23 23-48 4 R A S Q S I G T – – – – – – S I H Y V S E S I S Q Q S N S W H S R
ZA1B11 Vk12/13 12-46 2 R A S E N I Y S – – – – – – N L A A A T N L A D Q H F W G T M
ZA6A8 Vk21 21-5 2 R A S E S G D S Y – – S D S Y M H R A S I L E S Q Q N N R D P Y T
 ZA5E11 Vk23 23-39 5 R A S Q S I S D – – – – – – Y L H Y A S Q S I S Q N G H S F P L T
 ZA7H10  (b) Vk1 bb1 1 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P R T
ZA1E4 Vk23 23-39 5 R A S Q S I S D – – – – – – Y L H Y A S Q S I S Q N G H S F P L T
ZA1E5 (a) Vk8 8-21 2 K S S Q S L L N S R T R K N Y L A W A S T R E S K Q S Y N L Y – T
ZA2D8 (a) Vk8 8-21 2 K S S Q S L L N R R T R K N Y L A W A S T R E S K Q S Y N L Y – T
ZA6C10 VK4/5 ai4 1 T A S S S V S S S – – – – – Y L H S T S N L A S H Q Y H R S P P T
ZA3F7 (b) Vk1 bb1 1 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P R T
NZM-B ZB7D12 Vk1 cr1 1 R S S Q S I V H S – N G N T Y L E K V S N R F S F Q G S H V P P T
ZB7E10 Vk2 bd2 5 K S G Q S L L D S – D G K T Y L N L V S K L D S W Q G T H F P L T
ZB2C11 (c) Vk8 8-21 1 K S S Q S L L N S R T R K N Y L A W A S T R E S K Q S Y N L W – T
ZB4A12 (e) Vk2 bd2 5 K S G Q S L L D S – D G K T Y L N L V S K L D S W Q G T H F P L T
ZB7B1 (e) Vk2 bd2 5 K S S Q S L L D S – D G K T Y L N L V S K L D S W Q G T H F P L T
ZB4H7 Vk9/10 ba9 5 K A S Q D I N G – – – – – Y L S R A N R L V D L Q Y D E F P L T
 ZB7F11  (d) VkRF RF  5 R A S K S I S R – – – – – – Y L A S G S T L Q S L Q H N E Y P L T
ZB10B6 Vk21 21-2 2 R A S E S V D N Y – – G I S F M N A A S N Q G S Q Q S K E V P Y T
ZB5G11 Vk21 21-4 1 K A S Q S V D Y D – – G D S Y M N A A S N L E S Q Q S N E D P P T
ZB9A6 Vk23 23-39 5 R A S Q S I S D – – – – – – Y L H Y A S Q S I S Q N G H S F P L T
 ZB1A7 Vk1 bb1 1 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P R T
ZB2E5 Vk9/10 bv9 2 R A S Q D I G S – – – – – – S L N A T S S L D S L Q Y A S S P Y T
ZB2F12 Vk1 cv1 2 K S A K S L L N S – D G F T Y L D L V S N R F S F Q S N Y L P C T
ZB5D2 VK4/5 aq4 5 S A S S S V S – – – – – – – Y M C L T S N L A S Q Q W S S N P L T
ZB5F3 Vk24/25 hf24 2 R S S K S L L H S – N G N T Y L Y R M S N L A S M Q H L E Y P Y T
ZB9G6 Vk19/28 19-14 2 K A S Q N V R T – – – – – – A V A L A S I R H T L Q H W N Y P Y T
ZB2G14 Vk2 bd2 2 K S S Q S L L D S – D G K T Y L N L V S K L D S W Q G T H F P H T
 ZB5D3 Vk1 bb1 2 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P Y T
ZB2F10 Vk24/25 hf24 2 R S S K S L L H S – N G N T Y L Y R M S N L A S M Q H L E Y P Y T
ZB2G10 Vk12/13 12-44 1 R A S E N I Y S – – – – – – Y L A N A K T L A E Q H H Y G T P W T
ZB8A7 Vk9/10 cp9 2 S A S Q G I S N – – – – – – Y L N Y T S N L H S Q Q Y S K L P Y T
ZB10C9 Vk4/5 ai4 2 T A R S S V S S S – – – – – Y L H S T S N L A S H Q Y H L S P Y T
ZB4E2 (c) Vk8 8-21 1 K S S Q S L L N R R F T Q N Y L G W A S T R E S K Q S Y N L W – T
ZB5B4 Vk8 8-21 2 K S S Q S L L N S R T R K N Y L A W A S T R E S K Q S Y N L Y – T
ZB2D7 (d) VkRF RF  5 R T S K S I S K – – – – – – Y L A S G S T L Q S Q Q H N E Y P L T
ZB1D9 Vk4/5 kf4 5 C A S S S I S S N – – – – – Y L H R T S N L A S Q Q G S S I P L T
 ZB4D8  (d) Vk9/10 ba9 4 K A S Q S D K D – – – – – – Y L S Y A A N L A D Y N M V R A V – T
 ZB7D7 Vk4/5 ai4 2 T A R S S V S S S – – – – – Y L H S T S N L A S H Q Y H L S P Y T
 ZB1B11 Vk1 bb1 2 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P Y T
NZM-C ZCE1 Vk19/28 19-14 5 K A S Q N V R T – – – – – – A V A Y A S N R H T L Q H W N Y P L T
ZCH1 Vk4/5 aa4 1 S A S S S V S – – – – – – – Y M Y R T S N L A S Q Q Y H S Y P P T
ZCA3 VkRF RF 5 R A S K S I S R – – – – – – Y L A S G S T L Q S Q Q H N E C P L T
 ZCF4 Vk4/5 ai4 2 T A S S S V S S S – – – – – Y L H S T S N L A S H Q Y H R S P P T
ZCB1 Vk1 bb1 2 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P Y T
NZM-D ZDD2 Vk21 21-10 1 R A S E S V D S F – – D N S F M Y L T S N L E S Q Q N N E D P W T
 ZDB4 Vk21 21-5 1 R A S E S V D S Y – – G N S F M H R A S N L E S Q Q S N E D P R T
 ZDC1 Vk1 bb1 4 R S S Q S L V H S – N G N T Y L H K V S N R F S S Q S T H V P F T
 ZDC3 Vk2 bd2 5 K S S Q S L L D S – D G K T Y L N L V S K L D S W Q G T H F P – T
ZDA3 (f) Vk4/5 ay4 5 R A S S S I S S N – – – – – Y L H R T S I L A S Q Q G S S S P P R
ZDB2 (f) Vk4/5 ai4 2 T A S S S V S S S – – – – – Y L H T T S N L A S H Q Y H R S P Y T
ZDD1 Vk19/28 19-23 1 K A S Q D V G T – – – – – A V A W A S T R H T Q Q Y S S Y P R T
aAll mAbs are listed as ordered in Table I. Clonal membership is indicated using letters in parentheses. The entries for ZB3C7, ZB2C1, and ZA8C4 have been omitted
because these mAbs used   LCs.
bThe Vk family and germline (GL) gene usage for each mAb are depicted.
cAll CDR residues, following the numbering scheme adopted by the National Center for Biotechnology Information/IgBlast, are shown.Monoclonal ANAs from NZM2410 Mice 392
in the HC CDR3 regions of ANAs and non-ANAs are
fairly similar, the increased frequency of such residues ob-
served among the ANAs is likely to be the consequence of
antigen-driven selection.
Comparative analyses of previously rescued ANAs have
also revealed (less prominently) differences in the other
CDR regions (for review see reference 25). However, the
CDR1 and CDR2 regions of the NZM2410-derived
ANAs and non-ANAs were very similar, with only one
difference attaining statistical significance. Thus, the ANAs
exhibited an increased frequency of “S” residues at the
CDR2 position, H52, compared with the non-ANAs (P  
0.05). In reviewing the origin of this specific difference, it
was clear that this difference was entirely due to the in-
creased usage of VH5/7183 VH genes (that exhibited germ-
line-encoded S residues at H52), among the ANAs, as
depicted in Table II. Although there was a trend toward
increased N residues at H31 and reduced D residues at
H52–H56 among the ANAs (as noted previously in other
ANAs; reference 25), these differences fell short of statisti-
cal significance. Finally, no significant residue usage differ-
ences were noted in the LC of ANAs, compared with
those of non-ANAs.
Contributions of Somatic Mutation. Somatic mutation has
been accorded an important role in the generation of
ANAs (33, 34). As summarized in Table S2 (available at
http://www.jem.org/cgi/content/full/jem.20030132/DC1),
very little somatic mutation was noted in the LC and the
framework regions of the HCs, in both groups of Abs; in
contrast, the HC CDR1 and CDR2 regions of both the
ANAs and the non-ANAs exhibited high mutation fre-
quencies, with high replacement/silent ratios. In addition,
the mutation frequencies did not differ significantly be-
tween the two groups of Abs, when individual positions
within the CDR1 and CDR2 regions were examined (Ta-
ble S2). However, three HC CDR positions were of par-
ticular interest. H31, H50, and H56 of ANAs exhibited the
highest mutation frequencies ( 40%). More interestingly,
the replacement mutations at these three positions resulted
in a spectrum of amino acids that were quite different from
those seen at the corresponding positions of non-ANAs.
Although 70% of the mutations at H31 were to N or R
residues among the ANAs, the corresponding value was
36% among the non-ANAs (P   0.05). Likewise, ANAs
exhibited more mutations to Y residues at H50 (P   0.01),
and more mutations to “N/Y” residues H56 (P   0.05),
compared with the non-ANAs. Although these trends
were interesting, most fell short of statistical significance.
Clearly, larger datasets must be analyzed to investigate these
differences further. When we next examined the codons
that had been used to encode the aforementioned amino
acid residues, interesting, but similar, patterns were ob-
served in both groups of Abs. For example, in both the
ANAs and the non-ANAs, Rand N residues at H31 were
invariably the product of a single nucleotide mutation of
“AGC” (that encodes for “S”), which is germline-encoded
at the H31 position of several germline genes belonging to
the VH1/J558 (e.g., V23, MVARG2, etc.) and VH5/7183
(e.g., VH76–1BG, VH283, 7183.3b, and 7183.9, etc.) VH
families.
Finally, we examined the multimember clonal families
among the rescued ANAs. Of the six clonal families ob-
served, five consisted of two to three nonidentical mem-
bers each (Fig. 8), whereas the remaining clone (Table I,
clone “f”) consisted of two identical isolates. This was
consistent with the mutation frequencies listed in Table
VI, whereas the HC of these clones displayed high muta-
tion frequencies, particularly in the CDR regions, the LC
varied little from the germline sequences, for the most
part. In contrast to clones “A,” “B,” and “E,” clones “C”
and “D” exhibited intraclonal differences in ANA fine
specificity. Because both members of clone C possessed
the same germline-encoded VH1/J558 10B10S germline
gene, the few LC mutations exhibited by clone 4E2 must
have been responsible for the dsDNA reactivity profile of
this clone. In this context, the replacement mutation at
L27e, which results in an R residue, is particularly attrac-
tive. This is perhaps the first example of an instance where
somatic mutation of the LC partner may have been re-
Figure 7. The distribution of “R/K” and “D/E” residues in the HC
CDR3 regions of ANAs and non-ANAs. In A, the respective frequencies
of R/K and D/E residues at each of the HC CDR3 positions, H95–
H100a, among the NZM2410-derived ANAs (n   49) and non-ANAs
(n   40) are depicted. Differences (between ANAs and non-ANAs) that
attained statistical significance are denoted (*, P   0.05; **, P   0.01).
The solid line arrowhead indicates the alternating frequency peaks of
cationicity between H96 and H98 of ANAs; the dotted line arrowhead
indicates the alternating peaks of anionicity between H96 and H98
among the non-ANAs. There were too few sequences with CDR3 posi-
tions extending beyond H100a (Table III). In B, a similar analysis was
performed using previously reported ANAs (n   269) and non-ANAs
(n   3,600) (for review see reference 25). These control ANAs represent
269 previously documented ANAs drawn from 35 primary works, from
which clonal replicates have been removed; they consisted of 143 anti-
ssDNA, 103 anti-dsDNA, and 23 antinucleosome Abs (25). The control
“non-ANAs” represent the HCs of all Abs deposited in the Kabat data-
base. Differences that attained statistical significance are denoted (*, P   0.05;
**, P   0.01; ***, P   0.001).Liang et al. 393
sponsible for generating a dsDNA binder, beginning with
a nucleosome-restricted precursor.
Clone D is also very intriguing, in view of its LC diver-
sity. The strong dsDNA-binder, 4D8, is the most mutated
member of this clone, as it bears a V23 germline gene with
10 HC mutations, and a Vk9 germline gene (recombined to
Jk4), with 9 somatic mutations. Because its clonal siblings,
7F11 and 2D7, were recombined to Jk5 and possessed fewer
LC mutations, and because they did not bind dsDNA
(7F11), or bound dsDNA weakly (2D7), it is tempting to
speculate that 7F11 and 2D7 may be the products of LC re-
ceptor editing, beginning with the dsDNA-binding 4D8
clone as a precursor. Therefore, one might posit that LC re-
ceptor editing may potentially play a role in generating anti-
nucleosome specificities, beginning with a dsDNA binder.
Clearly, these suggestions are speculative, and need to be
tested using in vitro expression and mutagenesis studies.
Discussion
Although it is well established that anti-dsDNA Abs play
a cardinal role in the development of lupus, the pathogenic
potential of two closely associated specificities, antinucleo-
some Abs and antiglomerular Abs, have remained unclear.
As discussed earlier, antinucleosome ANAs have been doc-
umented in several murine models and clinical contexts
where end organ disease was distinctly absent (9–13). Al-
though these analyses support the notion that antinucleo-
some Abs that do not bind dsDNA may not be pathogenic,
isolated papers in experimental models have suggested that
these Abs may have the potential to induce renal disease
when complexed with nuclear antigens (19). In contrast to
anti-dsDNA and antinucleosome ANAs, an overlapping
specificity that is fairly well documented to be associated
with renal disease is the group of Abs that exhibit nephro-
philicity (4, 35, 36). Although the existence of these three
sets of specificities (anti-dsDNA, antinucleosome, and anti-
glomerular Abs) have been well recognized for some time,
little effort has been expended to directly compare the rela-
tive pathogenic capacities of these different specificities. In
particular, we sought to address two pressing questions in
this work as follows: (a) Are anti-dsDNA Abs more patho-
genic than antinucleosome Abs? and (b) Are glomerular-
binding ANAs more pathogenic than their nonnephro-
philic counterparts?
To address these questions, we took advantage of the
observation that NZM2410 lupus mice exhibited all three
serological specificities. As summarized in Figs. 3 and 4, the
answers to both those questions were in the affirmative.
First, antinucleosome Abs of both IgM and IgG isotypes
were relatively innocuous, in comparison to anti-dsDNA
ANAs. Second, although dsDNA-reactive Abs appeared to
be fairly pathogenic, the presence of any concomitant reac-
tivity to glomerular substrate significantly boosted their
pathogenic potential, as signified by the elevated pro-
teinuria and azotemia triggered by these Abs.
Several investigators have already noted in the past that
ANAs that also exhibited glomerular reactivity were signif-
icantly more pathogenic, both in murine models and in
human systemic lupus erythematosus (4, 35–39). Using a
multivariate analysis of parameters relating to 12 monoclo-
nal ANAs, Gilkeson et al. have reported that in vitro glo-
merular reactivity was the parameter with the best predic-
tive value for renal disease (37). They had also reported that
Figure 8. Somatic variations
between members of antibody
clones. 11 NZM2410-derived
monoclonal ANAs are depicted
that belonged to five indepen-
dent clones, A–E, as indicated in
Tables I, III, and IV. These
clones have been labeled the
same way as in Table I, except
that the mouse origin identifiers
(e.g., “ZA”, “ZB,” etc.) have
been omitted. DsDNA-reactive
clones are shaded in gray,
whereas exclusive nucleosome
binders are left unshaded. (top)
The HC somatic mutations rela-
tive to the closest HC germline
gene (indicated in oval labels
with dotted borders) are depicted.
(bottom) The LC somatic muta-
tions relative to the closest LC
germline gene (indicated in oval-
shaped labels with dotted borders)
are depicted. Thus, in clone “B,”
mAbs 7H10 and 3F7 vary from
the J558 germline gene, V23, by
6 or 10 residues, respectively, whereas they both bear the same unmutated LC Vk1 germline gene, bb1. Interestingly, whereas the first-listed two members
of Clone D, 7F11 and 2D7, possessed a mutated RF Vk germline gene, the third member possessed an entirely different LC gene that differed from the
Vk9 germline gene, ba9, by nine somatic mutations (not depicted).Monoclonal ANAs from NZM2410 Mice 394
the glomerular binding exhibited by most anti-dsDNA
ANAs was sensitive to DNase-I treatment. Thus, the
present findings are consistent with the prevailing notion
that the glomerular reactivity of most Abs may be depen-
dent on the presence of nuclear antigenic bridges (40–42).
On the other hand, polyreactive Abs and Abs that reacted
directly with intrinsic glomerular antigens have also been
shown to be nephritogenic (4, 43–48). Importantly, in ad-
dition to ANAs, polyreactive Abs, as well as Abs with spec-
ificity for the extracellular matrix are evidently more prom-
inent in the glomerular deposits of lupus kidneys (47–49).
It is reasonable to posit that the Abs with nephrophilicity
(irrespective of whether or not their glomerular binding is
mediated by nuclear antigenic bridges) may be the most
pathogenic because they may possess the greatest potential
to “latch” onto the glomerular basement membrane or ma-
trix. This could contribute to proteinuria in at least two
ways. First, the massive coating of the filtration barrier with
the nephrophilic Abs may compromise the charge barrier
to glomerular filtration, thus allowing serum proteins to be
lost. Second, the bound Abs may facilitate downstream Fc-
dependent pathogenic cascades to proceed most effectively.
Although both IgM and IgG Abs have the potential to fix
complement, only the IgG Abs have the capacity to engage
FcR-dependent events, such as those that serve to recruit
macrophages and neutrophils from the systemic circulation.
The critical role that these events play in engineering im-
mune-mediated nephritis is clearly demonstrated by the
phenotypes observed in FcR-deficient mice (50). This dif-
ference may explain why nephrophilic ANAs of the IgG
isotype appear to be more pathogenic than those of the
IgM isotype in the present work. However, one cannot ex-
clude the possibility that differences in avidity for the glo-
merular substrate may also be contributing to the observed
differences in pathogenicity between the two groups of Abs
examined in this paper.
At the other end of the spectrum, the antinucleosome
ANAs appear to be relatively harmless, owing perhaps to
the fact that they do not bind avidly to anioinic antigenic
substrates, such as DNA or the glomerular matrix. It is con-
ceivable that this species of ANAs only acquires pathoge-
nicity when coadministered with nucleosomes, which can
serve as antigenic bridges for glomerular binding (19, 42).
Finally, nonnephrophilic anti-dsDNA ANAs appear to
have an intermediate phenotype in terms of their patho-
genic potential. With respect to this observation, one could
envisage two possibilities. First, one could hypothesize that
although these Abs do not exhibit any nephrophilicity in
vitro, they may possess varying degrees of nephrophilicity
in vivo, perhaps mediated by nuclear antigenic bridges. Al-
ternatively, they may use other means of in vivo pathoge-
nicity as has been suggested (51, 52).
The findings reported in this paper have important rami-
fications in clinical diagnostics. Presently, several vendors
market antinucleosome ELISA kits, promoting these Abs as
being a better predictor of disease in systemic lupus erythe-
matosus. Unfortunately, the antinucleosome ELISA detects
both the anti-dsDNA Abs (that are pathogenic) as well as
the non-dsDNA binders (that are evidently not patho-
genic). Therefore, the results of these tests should be con-
sidered in conjunction with the results of the anti-dsDNA
ELISA. Thus, the presence of serum antinucleosome Abs
in the absence of anti-dsDNA Abs may be an indicator of
good prognosis. Indeed, genetic evidence for this notion
has recently been advanced (11). On the other hand, test-
ing for glomerular-binding specificities may be particularly
useful in identifying patients with worse prognosis, which
has been described previously (35, 36).
Another important contribution of this work revolves
around the molecular structure of ANAs; in particular, the
following observations are noteworthy. First, several of the
observed features, including the IgM isotype, the increased
VH5/7183 VH family usage (with the attendant differences
in the amino acid usage at certain CDR positions), and
their polyreactive specificity profiles are all reminiscent of
the signatures of “natural autoantibodies” typically pro-
duced by B1 cells (53–55). The NZM2410 strain is known
to harbor a massively enlarged B1 cell pool, both in the
spleens as well as in the peritoneum, largely as a conse-
quence of the lupus susceptibility locus, Sle2 (56). There-
fore, it is perhaps not surprising that approximately one
fourth of the Abs rescued from NZM2410 mice possessed
these signatures, presumably representing the products of
B1 cells. Interestingly, approximately one third of the
VH5/7183-encoded Abs were dsDNA/glomeruli dual re-
active, whereas most of the rest were IgM antihistone/nu-
cleosome Abs. It should be pointed out that most of these
features, including the usage frequencies of VH5/7183, are
very similar to the observations made with ANAs derived
from the BWF1 lupus strain, another model that exhibits
prominent B1 cell expansion (20). 
With the aforementioned exception, the rescued ANAs
and non-ANAs exhibited almost identical VH and Vk gene
usages, similar Jk usage profiles, HC CDR3 and LC CDR1
lengths, mutation frequencies, as well as similar usage fre-
quencies of almost all residues at most CDR positions. In
earlier comparative papers (20–25, 57, 58), some of those
features have been reported to apparently distinguish ANAs
from non-ANAs; however, it remains possible that some of
the latter differences may be the consequence of using the
Kabat database as a normal control. Indeed, when we com-
pared the CDR regions of NZM2410-derived ANA HCs
with the Kabat database of normal HCs, a total of 39 residue
differences were noted at a significance level of P   0.05
(with 16 of these exceeding the threshold of P   0.001), in-
cluding several differences that involved nonpolar, conser-
vative changes (unpublished data). The corresponding statis-
tic for the LC comparisons (i.e., NZM2410-derived ANAs
vs. Kabat database) was 49 (P   0.05) and 13 (P   0.001)
residues, respectively.
In a recent analysis in which all murine ANAs rescued
thus far were pooled and compared, although several
“trends” were noted in the CDR2 regions of ANAs, most
of these differences fell short of statistical significance; the
only difference of prominence was noted at H52, where
non-ANAs (from the Kabat database) had significantlyLiang et al. 395
more D residues, compared with the ANAs (25). This re-
ported difference coincides with the only significant HC
CDR2 difference noted in the present work, where the
NZM2410-derived ANAs exhibit more S residues than
non-ANAs, apparently as a consequence of differences in
VH germline gene usage. As site-directed mutagenesis
studies have revealed that polar residues in the vicinity of
H52 can potentially impact DNA binding (59), it is reason-
able to posit that the residue differences noted at H52 may
be the result of DNA-driven selection of VH germline
genes that possess polar residues at these positions.
In contrast with the aforementioned residue differences,
the sequence differences observed in ANA HC CDR3 re-
gions were truly unmistakable. Previous investigators have
observed that the HC of ANAs were more cationic due to
the possession of R residues (20–25, 33, 57, 58, 60–62).
Computer modeling papers have accorded potentially im-
portant roles for CDR3 R residues in making contact with
nuclear antigens (63, 64). In addition, crystal structure anal-
yses have elegantly portrayed the different mechanisms
through which CDR3 R residues might facilitate DNA
binding (65–69). Finally, a couple of groups have directly
confirmed that targeted mutagenesis of R at H96 indeed
mitigates DNA-binding (59, 70).
In studying a large panel of BWF1-derived ANAs, Mar-
ion and colleagues reported that the increased prominence
of R residues at H98–H100a was a hallmark of ANAs (57–
58). In addition, this work also revealed that the CDR3 re-
gions of ANA HC had significantly fewer R residues at
H97, suggesting that an R at H97 might actually destabilize
key structural features of the antigen-binding groove, thus
precluding dsDNA reactivity (58). In collecting and analyz-
ing all murine ANAs characterized to date, Chen et al. re-
ported that these patterns (i.e., increased R at H96 and
H98–H100a, but not at H97) were key features of anti-
ssDNA and anti-dsDNA Abs, but not antinucleosome Abs
(25). In further support of these findings, crystal structure
analysis of an anti-dsDNA Ab, Jel72, revealed that its CDR3
R residues at H98-H100a were indeed extending into the
major groove of the cognate dsDNA target (69). Finally, the
critical role played by R residues at H100 has been directly
demonstrated by site-directed mutagenesis works (61, 71,
72). In contrast to the proposed role of charged residues at
the aforementioned CDR3 positions, cationicity did not ap-
pear to be important at H95 (72). By analyzing ANAs and
non-ANAs rescued from the same mice, the present paper
confirms the aforementioned findings and further uncovers
an intriguing CDR3 motif among the ANAs, in the aggre-
gate, distinguished by alternating peaks of cationicity.
Aside from the contribution of the HC, it appears likely
that the LC partner may also be playing a role in modulat-
ing DNA binding, as has been described previously (73–
78). As an example, the nucleosome binder, ZDB4, fails to
bind dsDNA, despite possessing R residues at H98 and
H100 (Tables I and III). Interestingly, it possessed a rather
anionic LC partner with D/E residues in CDR1 (L27 and
L27c), CDR2 (L55), and CDR3 (L93 and L94). It is
tempting to postulate that this LC partner might have ve-
toed dsDNA binding, as has been described for other LC
partners (76). On the other hand, the strong dsDNA
binder, ZDD1, exhibited no R/K residues in all three of its
HC CDR regions and had a rather innocuous-looking
CDR3 sequence, “GTGTGFAY”; interestingly, its LC
partner possessed R residues in CDR2 (L54) and CDR3
(L96). It is tempting to posit that this LC partner might
have been an important factor in conferring DNA reactiv-
ity to ZDD1. Finally, the potential contributions of LC in
modulating reactivity to different nuclear antigens (i.e., ds-
DNA vs. nucleosomes) is also evident from the observed
clonal relationships among the rescued ANAs (Fig. 8).
To conclude, although anti-dsDNA ANAs may be
pathogenic, it is clear that nephrophilic isolates among
these Abs (most of which bind glomerular substrate via nu-
clear antigenic bridges) are evidently the most pathogenic.
In contrast, antinucleosome Abs appear to be rather innoc-
uous. In addition, these studies suggest that ANAs and
non-ANAs may be fairly similar in HC and LC structure
and sequence, with a few major differences; cationic resi-
dues were particularly prominent at the alternating HC
CDR3 positions, H96, H98, and H100, whereas these res-
idues appeared to be excluded from the intervening posi-
tions, H97 and H99. The positioning of polar residues at
specific CDR regions of ANAs may be the consequence of
altered germline gene usage (as suggested by the observed
differences at H52), or somatic mutations (as suggested by
the differences noted at H31, H50, and H56). Clearly, the
biological significance of these intriguing motifs and CDR
residue differences needs to be verified using expression
and mutagenesis studies.
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